PMDAsafety guidance83% confidence
[IBENTO][IBENTO]Workshop on New Approach Methodologies (NAMs) Held following ICCR-20
Source: PMDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Merck.
Regulatory Analysis
PMDA regulatory document relevant to this signal.
Supporting Context
- Therapeutic area
- Cardiovascular · PCSK9 Inhibition
- Sub-indication
- General
Related signal: Merck Publishes Method for Scalable Synthesis of Oral PCSK9 Inhibitor Enlicitide Decanoate